FDA Grants Interchangeable Designation to Pfizer ’s Abrilada, Biosimilar to AbbVie ’ s Humira

On Oct. 5, Pfizer announced that Abrilada (adalimumab-afzb), its biosimilar to Humira (adalimumab), had received an interchangeable designation from the U.S. Food & Drug Administration (FDA).

Source: The Rheumatologist - October 5, 2023 Category: Rheumatology Authors: Keri Losavio Tags: Biologics/DMARDs Drug Updates Humira interchangeability Source Type: research